Confirmation
Open All
Tenecteplase
Tenecteplase
Classification
High alert medication
Thrombolytic agent
Indications
ACP with endorsement and training: Coronary reperfusion in ST elevation myocardial infarction
CCP: Coronary reperfusion in ST elevation myocardial infarction
Contraindications
Patient must meet criteria for entry into CHAMP pathway
- Active internal bleeding
- History of cerebrovascular accident
- Intracranial or intraspinal surgery, or trauma within 2 months
- Intracranial neoplasm, ateriovenous malformation, or aneurysm
- Known bleeding diathesis
- Severe uncontrolled hypertension
- Known hypersensitivity to tenecteplase or any components of the formulation
Adult dosages
Follow weight and age-based dosing
For intravenous administration only. Push over 5 seconds.
Pediatric Considerations And Dosing
Not authorized in pediatrics
Mechanism Of Action
Tenecteplase is a modified form of human tissue plasminogen activator (tPA) binding to fibrin and converting plasminogen to plasmin.
Pharmacokinetics
Following a single bolus dose of tenecteplase:
- Plasma half-life: 20-24 minutes
- Distribution: plasma
- Metabolism: liver
Adverse Effects
The most frequent adverse reaction associated with tenecteplase is bleeding.
Overdose
Overdose is considered unlikely.
Warning And Precautions
- Coronary reperfusion may result in reperfusion arrhythmias.
- Internal and external bleeding may occur. Monitor all potential bleeding sites. Minimize venous and arterial punctures.
Drug Interactions
- Antiplatelet agents may enhance the anticoagulant effect of thrombolytic agents and may in turn have their antiplatelet effects enhanced by thrombolytic agents.
- Tranexamic acid may diminish the therapeutic effect of thrombolytic agents.
Classification
High alert medication
Thrombolytic agent
Indications
ACP with endorsement and training: Coronary reperfusion in ST elevation myocardial infarction
CCP: Coronary reperfusion in ST elevation myocardial infarction
Contraindications
Patient must meet criteria for entry into CHAMP pathway
- Active internal bleeding
- History of cerebrovascular accident
- Intracranial or intraspinal surgery, or trauma within 2 months
- Intracranial neoplasm, ateriovenous malformation, or aneurysm
- Known bleeding diathesis
- Severe uncontrolled hypertension
- Known hypersensitivity to tenecteplase or any components of the formulation
Adult dosages
Follow weight and age-based dosing
For intravenous administration only. Push over 5 seconds.
Pediatric Considerations And Dosing
Not authorized in pediatrics
Mechanism Of Action
Tenecteplase is a modified form of human tissue plasminogen activator (tPA) binding to fibrin and converting plasminogen to plasmin.
Pharmacokinetics
Following a single bolus dose of tenecteplase:
- Plasma half-life: 20-24 minutes
- Distribution: plasma
- Metabolism: liver
Adverse Effects
The most frequent adverse reaction associated with tenecteplase is bleeding.
Overdose
Overdose is considered unlikely.
Warning And Precautions
- Coronary reperfusion may result in reperfusion arrhythmias.
- Internal and external bleeding may occur. Monitor all potential bleeding sites. Minimize venous and arterial punctures.
Drug Interactions
- Antiplatelet agents may enhance the anticoagulant effect of thrombolytic agents and may in turn have their antiplatelet effects enhanced by thrombolytic agents.
- Tranexamic acid may diminish the therapeutic effect of thrombolytic agents.